Celgene Corporation (NASDAQ:CELG) just released results from a phase 3, randomized, double-blind, international clinical REMARC study to investigate its pipeline drug Revlimid against a …
Analyst Brian Skorney from Baird discussed Gilead Sciences, Inc. (NASDAQ:GILD) and Celgene Corporation (NASDAQ:CELG) ahead of their second-quarter earnings reports.
J.P.
Celgene Corporation (NASDAQ:CELG) announced that the European Commission (EC) has approved REVLIMID® (lenalidomide) for the treatment of adult patients with relapsed or refractory mantle …
Analysts weighed in how the FDA clinical hold Juno Therapeutics Inc (NASDAQ:JUNO) received affects its business as well as companies with similar drugs …
Canaccord analyst John Newman was out pounding the table on Celgene Corporation (NASDAQ:CELG) Friday, reiterating a Buy rating and price target of $156, which represents a …
Analyst Brian Abrahams from Jefferies provides his insight on the different drug developments concerning Gilead Sciences, Inc. (NASDAQ:GILD) and Celgene Corporation (NASDAQ:CELG).
The aftershocks from Brexit continue to weigh on the markets, with the iShares Nasdaq Biotech ETF (IBB) down more than 3% Monday. Among the equities in …
The Abramson Cancer Center at the University of Pennsylvania, The Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center, the Sidney Kimmel …
Celgene Corporation (NASDAQ:CELG) announced that during its June meeting the Company’s Board of Directors authorized the repurchase of up to an additional $3.0 billion …
